The estimated Net Worth of Gail Frances Mc Intyre is at least $714 Тысяча dollars as of 29 June 2021. Gail Intyre owns over 1,000 units of Aravive Inc stock worth over $445 and over the last 6 years he sold ARAV stock worth over $0. In addition, he makes $713,495 as President, Chief Executive Officer и Director at Aravive Inc.
Gail has made over 2 trades of the Aravive Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of ARAV stock worth $5,350 on 29 June 2021.
The largest trade he's ever made was buying 8,000 units of Aravive Inc stock on 4 December 2020 worth over $46,160. On average, Gail trades about 1,000 units every 23 days since 2019. As of 29 June 2021 he still owns at least 11,137 units of Aravive Inc stock.
You can see the complete history of Gail Intyre stock trades at the bottom of the page.
Dr. Gail F. McIntyre Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. McIntyre has served as the Company’s Chief Scientific Officer since February 2019. Dr. McIntyre also served as the Company’s Senior Vice President of Research and Development from October 12, 2018, when the Company, then known as Versartis, Inc., and Aravive Biologics, Inc. (“Private Aravive”), completed a merger and reorganization (the “Merger”), pursuant to which Private Aravive survived as the Company’s wholly owned subsidiary, until February 2019 and served as Private Aravive’s Senior Vice President of Research and Development from January 2017 to October 2018 and a consultant to Private Aravive from August 2016 until January 2017. Having brought multiple drugs to market, Dr. McIntyre has more than 25 years of experience in drug development, strategic business development, licensing and M&A activities. Dr. McIntyre has served as a principal at IntelliDev Consulting, LLC providing consulting services to several biotechnology companies for three years, while also serving as Vice President of Development for Meryx, Inc. from January 2014 until January 2016. Prior to that, Dr. McIntyre held the position of Senior Vice President of Research at Furiex Pharmaceuticals, Inc. and previously served as head of PPD’s compound partnering business. At both Furiex and PPD, she strategized and managed all preclinical and clinical activities for drug development programs and was responsible for identification of new partnering opportunities and technical due diligence for both in-licensing opportunities and new business acquisitions. At PPD, she led the partnering and the in-licensing of Alogliptin from Syrrx, Inc. at pre-IND stage and the licensing to Takeda at Phase 2. Dr. McIntyre received her B.A. in Biology from Merrimack College. She earned M.S. and Ph.D. degrees in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill.
As the President, Chief Executive Officer и Director of Aravive Inc, the total compensation of Gail McIntyre at Aravive Inc is $713,495. There are no executives at Aravive Inc getting paid more.
Gail McIntyre is 57, he's been the President, Chief Executive Officer и Director of Aravive Inc since 2020. There are 6 older and 4 younger executives at Aravive Inc. The oldest executive at Aravive Inc is Fredric Eshelman, 72, who is the Independent Chairman of the Board.
Gail's mailing address filed with the SEC is C/O ARAVIVE, INC., RIVER OAKS TOWER,, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON, TX, 77098.
Over the last 6 years, insiders at Aravive Inc have traded over $107,045 worth of Aravive Inc stock and bought 151,333 units worth $1,102,898 . The most active insiders traders include Srinivas Akkaraju, Fredric N Eshelman Ventures... и Shahzad Malik. On average, Aravive Inc executives and independent directors trade stock every 75 days with the average trade being worth of $11,962. The most recent stock trade was executed by Fredric N Eshelman Ventures... on 1 April 2022, trading 4,545,455 units of ARAV stock currently worth $181,818.
versartis, inc. (nasdaq: vsar) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. the company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. versartis’ mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. learn more at www.versartis.com.
Aravive Inc executives and other stock owners filed with the SEC include: